O11: MYOFERLIN: A NOVEL BIOMARKER OF RADIOSENSITIVITY IN LOCALLY ADVANCED RECTAL CANCER

Abstract Introduction Our proteomic data has validated that high levels of the protein myoferlin confers poorer response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Myoferlin plays a role membrane repair and VEGF signal transduction, is associated with worse prognosis numerous other epithelial cancers. We aim assess impact on radiosensitivity Method Clonogenic assays were performed using immortalised colorectal cancer cells (HCT116,HT29,LIM,MDST8) survival at escalating radiation doses following knockdown siRNA or small molecular inhibitor(WJ460). 3D models (spheroids) used examine effect WJ460 tumour growth. Result Quantification immunoblotting demonstrated MDST8 LIM higher expressors than HCT116 HT29. Higher correlated increasing radio-resistance as calculated by colony formation efficiency (CFE). Using clonogenic assays, treated increased compared controls across all doses, most significantly 4Gy. Treatment spheroids reduced growth (p<0.05), limiting considerably more treatment current gold standard 5-FU. spheroid volume day 15; 4.96um3,5-FU 6.74um3,DMSO 24.9um3. Conclusion Inhibition cells, inhibitor reduces models. Further work required further validate its potential use biomarker Take-home message have found poor Manipulation this sensitises radiotherapy.